Sirolimus (albumin - bound)

DRUG2 trials

Sponsors

Fudan University, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions

Advanced Breast CancerAdvanced HR - Positive, HER2 - Negative Breast CancerResistant to (Neo)Adjuvant Endocrine Therapy

Phase 1

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

Not yet recruitingNCT06941142

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Advanced Breast Cancer

Start: 2025-04-30End: 2028-06-30Target: 382Updated: 2025-04-23

Unknown Phase

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

RecruitingNCT06856200

Fudan UniversityAdvanced HR - Positive, HER2 - Negative Breast Cancer, Resistant to (Neo)Adjuvant Endocrine Therapy

Start: 2025-02-28End: 2026-06-30Target: 36Updated: 2025-03-04